Background: Several publications describe HIV-1 RNA false-negative results or viral load underquantitation associated with Communauté Européenne(CE)-marked qualitative or quantitative nucleic acid amplification technique (NAT) assays. 6 cases occurred during blood screening in Germany, with 2 of them causing HIV-1 transmissions to recipients of blood components. The implicated NAT assays were mono-target assays amplifying in different viral genome regions (gag or long terminal repeat). Methods: Specimens characterized by HIV-1 NAT underquantitation or false-negative NAT results were comparatively investigated in CE-marked HIV-1 NAT systems of different design to identify potential reasons. The target regions of the viral nucleic acids were sequenced and these sequences compared to primers and probes of the assays. Potential risk minimization measures were considered for quantitative and blood-screening HIV-1 NAT systems. Results: Nucleotide sequencing of the viral target region in cases of HIV-1 RNA underquantitation or false-negative test results revealed new HIV-1 variants that were mismatched with primers and probes used in some mono-target assays. So far, dualtarget NAT assays have not been associated with mismatch-based false-negative test results. From 2015, the Paul Ehrlich Institute will request HIV-1 NAT assays of dual-target design or an analogous solution for further reducing the risk in blood screening. Conclusion: HIV differs from other blood-borne viruses with regard to its fast evolution of new viral variants. The evolution of new sequences is hardly predictable; therefore, NAT assays with only 1 target region appear to be more vulnerable to sequence variations than dual-target assays. The associated risk may be higher for HIV-1 NAT assays used for blood screening compared to quantitative assays used for monitoring HIV-1-infected patients. In HIV-1 screening NAT assays of dual-target design may adequately address the risk imposed by new HIV-1 variants.

Keywords:
HIV-1 nucleic acid amplification technique, Blood safety, HIV-1 variant
1.
European Centre for Disease Prevention and Control: Annual Epidemiological Report 2012. Reporting on 2010 surveillance data and 2011 epidemic intelligence data. Stockholm: ECDC; 2013. www. ecdc.europa.eu/en/publications/Publications/Annual-Epidemiological-Report-2012.pdf.
2.
Offergeld R, Ritter S, Quabeck L, Hamouda O: HIV-, HCV-, HBV- und Syphilissurveillance unter Blutspendern in Deutschland 2008-2010. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012;55:907-913.
3.
Roth WK, Busch MP, Schuller A, et al.: International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang 2012;102:82-90.
4.
Paul-Ehrlich-Institut. Stufenplan: Verminderung des Risikos von HIV-1-Infektionen durch zelluläre Blutprodukte und gefrorenes Frischplasma Anordnung der Testung auf HIV-1-RNA mit Nukleinsäure-Amplifikationstechniken. Bundesanzeiger 2003;103:12269.
5.
Holmes H, Davis C, Heath A, Hewlett I, Lelie N: An international collaborative study to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques. J Virol Methods 2001;92:141-150.
6.
Nübling CM, Chudy M, Löwer J: Validation of HCV-NAT assays and experience with NAT application for blood screening in Germany. Biologicals 1999;27:291-294.
7.
Nübling CM, Heiden M, Chudy M, Kress J, Seitz mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions. Transfusion 2009;49:1850-1858.
8.
Schmidt M, Korn K, Nuebling CM, Chudy M, Kress J, Horst HA, Geusendam G, Hennig H, Sireis W, Rabenau H, Doerr HW, Berger A, Hour-far MK, Gubbe K, Karl A, Fickenscher H, Tischer K, Babiel R, Seifried E, Guertler L: First transmission of HIV-1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion 2009;49:1836-1844.
9.
Edelmann A, Kalus U, Oltmann A, Stein A, Unbehaun A, Drosten C, Kruger DH, Hofmann J: Improvement of an ultrasensitive human immunodeficiency virus type 1 real-time reverse transcriptase-polymerase chain reaction targeting the long terminal repeat region. Transfusion 2010;50: 685-692.
10.
Foglieni B, Candotti D, Guarnori I, Raffaele L, Berzuini A, Spreafico M, Orani A, Rossotti R, Rossi D, Allain JP, Prati D: A cluster of human immunodeficiency virus type 1 recombinant form escaping detection by commercial genomic amplification assays. Transfusion 2011;51:719-730.
11.
Chudy M, Weber-Schehl M, Pichl L, Jork C, Kress J, Heiden M, Funk MB, Nübling CM: Blood screening nucleic acid amplification tests for human immunodeficiency virus type 1 may require two different amplification targets. Transfusion 2012;52:431-439.
12.
Müller B, Nübling CM, Kress J, Roth K, De Zolt S, Pichl L: How safe is safe: new HIV-1 variants missed by nucleic acid testing. Transfusion 2013;53(suppl 3):2422-2430.
13.
Damond F, Roquebert B, Benard A, Collin G, Miceli M, Yeni P, Brun-Vezinet F, Descamps D: Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays. J Clin Microbiol 2007;45: 3436-3438.
14.
Wirden M, Tubiana R, Marguet F, Leroy I, Simon A, Bonmarchand M, Ait-Arkoub Z, Murphy R, Marcelin AG, Katlama C, Calvez V: Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes. J Clin Microbiol 2009;47:1543-1545.
15.
Pyne MT, Brown KL, Hillyard DR: Evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test and identification of rare polymorphisms potentially affecting assay performance. J Clin Microbiol 2010;48:2852-2858.
16.
Korn K, Weissbrich B, Henke-Gendo C, Heim A, Jauer CM, Taylor N, Eberle J: Single-point mutations causing more than 100-fold underestimation of human immunodeficiency virus type 1 (HIV-1) load with the Cobas TaqMan HIV-1 real-time PCR assay. J Clin Microbiol 2009;47:1238-1240.
17.
Sizmann D, Glaubitz J, Simon CO, Goedel S, Buergisser P, Drogan D, Hesse M, Kroh M, Simmler P, Dewald M, Gilsdorf M, Fuerst M, Ineichen R, Kirn A, Pasche P, Wang Z, Weisshaar S, Young K, Haberhausen G, Babiel R: Improved HIV-1 RNA quantitation by COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 using a novel dual-target approach. J Clin Virol 2010;49:41-46.
18.
Damond F, Avettand-Fenoel V, Collin G, Roquebert B, Plantier JC, Ganon A, Sizmann D, Babiel R, Glaubitz J, Chaix ML, Brun-Vezinet F, Descamps D, Rouzioux C: Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification. J Clin Microbiol 2010;49:1413-1416.
19.
European Commission. Commission Decision of 3 February 2009 amending Decision 2002/364/EC on common technical specifications for in vitro-diagnostic medical devices (2009/108/EC). Official Journal of the European Union 2009; L39/34-L39/49.
20.
Nübling CM, Unger G, Chudy M, Raia S, Löwer J: Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion 2002;42:1037-1045.
21.
Paul-Ehrlich-Institut. Bekanntmachung über die Zulassung von Arzneimitteln - Abwehr von Arzneimittelrisiken - Vom 15. Juni 2012. Anordnung von Auflagen zu den Zulassungen für zelluläre Blutkomponenten und gefrorene Frischplasmen, hier: Anordnung von Maßnahmen zur Risikominimierung beim Einsatz von HIV-1 NAT-Testsystemen. BAnz AT 2012; 2.09.2012 B6.
© 2014 S. Karger GmbH, Freiburg
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.